Zymeworks (NYSE:ZYME - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Zymeworks to post earnings of ($0.31) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Zymeworks (NYSE:ZYME - Get Free Report) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.19. Zymeworks had a negative net margin of 156.12% and a negative return on equity of 26.20%. The business had revenue of $16.93 million during the quarter, compared to the consensus estimate of $18.32 million. On average, analysts expect Zymeworks to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Zymeworks Price Performance
Shares of NYSE:ZYME traded down $0.44 during trading on Thursday, reaching $8.11. 426,623 shares of the company's stock traded hands, compared to its average volume of 574,558. The company has a 50 day moving average of $10.59 and a 200-day moving average of $9.62. The stock has a market capitalization of $572.31 million, a P/E ratio of -4.66 and a beta of 1.14. Zymeworks has a 12 month low of $6.01 and a 12 month high of $13.14.
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Recommended Stories
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
